Aeterna Zentaris has been granted a patent for a method to measure growth hormone levels in children. The method involves administering macimorelin orally to the child and collecting blood samples within 60 minutes. If the peak growth hormone level is below a certain threshold, it indicates pituitary-related growth hormone deficiency. The patent also covers treating the deficiency with synthetic human growth hormone. GlobalData’s report on Aeterna Zentaris gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aeterna Zentaris, nanoemulsion cosmetics was a key innovation area identified from patents. Aeterna Zentaris's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method for diagnosing and treating growth hormone deficiency in children
A recently granted patent (Publication Number: US11644474B2) describes a method for detecting and treating growth hormone deficiency in human children. The method involves several steps. First, the child is orally administered with macimorelin at a dosage of approximately 1 mg per kg bodyweight. Then, the growth hormone level is measured in either two or three blood samples taken at specific time intervals after the administration of macimorelin. The highest growth hormone level obtained from these samples is compared to a predetermined threshold value of about 17 ng/ml. If the highest growth hormone level is lower than the threshold value, the child is determined to have growth hormone deficiency. Conversely, if the highest growth hormone level is equal to or higher than the threshold value, the child is determined to not have growth hormone deficiency. In the case of a positive diagnosis of growth hormone deficiency, the child is treated by injecting an effective amount of synthetic human growth hormone.
The patent also provides variations in the method. The blood samples used for measuring growth hormone levels can be serum samples, plasma samples, or whole blood samples. Additionally, the macimorelin can be administered in a composition that includes saccharin. The composition may consist of 3.5% w/w macimorelin free base, 93.1% w/w spray-dried lactose monohydrate, 2.0% w/w Type A crospovidone, 0.1% w/w colloidal silicon dioxide, 1.0% w/w sodium stearyl fumarate, and 0.3% w/w saccharin sodium dihydrate.
In summary, the granted patent outlines a method for detecting and treating growth hormone deficiency in human children. By administering macimorelin and measuring growth hormone levels in blood samples, the method allows for the determination of growth hormone deficiency based on a predetermined threshold value. If growth hormone deficiency is diagnosed, the child can be treated with synthetic human growth hormone. The patent also provides variations in terms of the type of blood samples used and the composition of macimorelin administration.
To know more about GlobalData’s detailed insights on Aeterna Zentaris, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
